menu
    • menu
    [{"orgOrder":0,"company":"Kuria Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"KTX-1161","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kuria Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kuria Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kuria Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kuria Therapeutics","sponsor":"Scohia Pharma","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"JAPAN","productType":"Other Small Molecule","year":"2022","type":"Licensing Agreement","leadProduct":"KTX-101","moa":"Nrf2","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Kuria Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Kuria Therapeutics \/ Kuria Therapeutics","highestDevelopmentStatusID":"5","companyTruncated":"Kuria Therapeutics \/ Kuria Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Kuria Therapeutics

    Menu

    Kuria Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kuria Therapeutics

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed

                            Kuria Therapeutics

                            U.S.A arrow
                            Boulder Peptide
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KTX-1161

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disea...

                            Details : KTX-1161 is a topical ophthalmic solution formulation of SCO-116, a novel Nrf2 activator being developed to treat patients with diseases of the corneal endothelium, including patients with Fuchs’ endothelial corneal dystrophy and patients undergoing ca...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 17, 2023

                            Lead Product(s) : KTX-1161

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kuria Therapeutics

                            U.S.A arrow
                            Cell Therapy
                            Not Confirmed

                            Kuria Therapeutics

                            U.S.A arrow
                            Cell Therapy
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : KTX-101

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Recipient : Scohia Pharma

                            Deal Size : $67.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights t...

                            Details : Under the agreement, Kuria may develop, manufacture, and commercialize worldwide the locally delivered formulations of SCO-116, one of SCOHIA’s internally discovered novel Nrf2 activators, for prevention and/or treatment of eye and skin diseases.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 27, 2022

                            Lead Product(s) : KTX-101

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Recipient : Scohia Pharma

                            Deal Size : $67.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth